Diabetes Solutions Landscape Phase 3, Part 2

Part
01
of two
Part
01

Diabetes Solutions Landscape - Cardio-Metabolic Identify, Treat, Slow Progression, Rows 8-14

Please see the attached spreadsheet.
Part
02
of two
Part
02

Diabetes Solutions Landscape - Cardio-Metabolic Identify, Treat, Slow Progression, Rows 15-22

We reviewed the solutions presented in rows 15-22 in the US CM ITS Full List ab and determined whether they meet the balance of the client’s inclusion criteria for categories three and four. The solutions reviewed are BePatient App, GlucoMe, InXite Smartcare, Bluedrop Medical, Preventicus, Medisafe, Catalia Health — Mabu, and Cameraeyes. We compiled our findings in the attached spreadsheet.

OVERVIEW

BePatient App, GlucoMe, InXite Smartcare, Bluedrop Medical, Preventicus, Medisafe, and Catalia Health — Mabu were identified to fit both inclusion criteria 3 and 4.

GlucoMe and Cameraeyes fit only inclusion criteria 3, but not 4. For these two solutions, we found no proof of them being in the clinical research stage of development or beyond this stage, raising more than $3 million in funding, reaching at least 10,000 registered users, publishing proven clinical outcomes, or having more than 5 articles published about them.

Our findings have been compiled in rows 15-22 of the attached spreadsheet.
Sources
Sources

From Part 01